6FN Stock Overview
Operates as a pharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Klaria Pharma Holding AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.025 |
| 52 Week High | SEK 0.076 |
| 52 Week Low | SEK 0.01 |
| Beta | 0.55 |
| 1 Month Change | 6.96% |
| 3 Month Change | -42.79% |
| 1 Year Change | -36.27% |
| 3 Year Change | -95.69% |
| 5 Year Change | n/a |
| Change since IPO | -96.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6FN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.4% | -0.2% | -0.1% |
| 1Y | -36.3% | -16.7% | 7.4% |
Return vs Industry: 6FN underperformed the German Pharmaceuticals industry which returned -16.7% over the past year.
Return vs Market: 6FN underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 6FN volatility | |
|---|---|
| 6FN Average Weekly Movement | 29.3% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6FN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6FN's weekly volatility has decreased from 36% to 29% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 4 | Scott Boyer | www.klaria.com |
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction.
Klaria Pharma Holding AB (publ.) Fundamentals Summary
| 6FN fundamental statistics | |
|---|---|
| Market cap | €4.81m |
| Earnings (TTM) | -€3.64m |
| Revenue (TTM) | n/a |
-7.7x
P/S Ratio-1.3x
P/E RatioIs 6FN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6FN income statement (TTM) | |
|---|---|
| Revenue | -SEK 7.15m |
| Cost of Revenue | SEK 0 |
| Gross Profit | -SEK 7.15m |
| Other Expenses | SEK 34.49m |
| Earnings | -SEK 41.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 100.00% |
| Net Profit Margin | 582.62% |
| Debt/Equity Ratio | 0% |
How did 6FN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 21:39 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Klaria Pharma Holding AB (publ.) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Sule | Redeye |
| Ethel Szpilman Luvall | Redeye |